查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372920

敗血症診斷市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按技術、產品、診斷方法、病原體、地區、競爭細分

Sepsis Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Technology, By Product, By Diagnostic Method, By Pathogen, and By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球膿毒症診斷市場價值為6.853 億美元，預計在預測期內將出現令人印象深刻的成長，到2028 年年複合成長率為7.22%。膿毒症是一種危及生命的疾病，當身體對感染的反應變得嚴重時，就會發生敗血症。失調，導致廣泛的炎症，並可能導致多重器官功能障礙或衰竭。這是一種嚴重且進展迅速的疾病，需要立即就醫和治療。敗血症通常始於感染，感染可能由細菌、病毒、真菌或寄生蟲引起。感染可能有多種來源，例如傷口、泌尿道感染、呼吸道感染或感染的手術部位。當身體檢測到感染時，免疫系統會透過釋放化學物質來抵抗入侵的病原體。這種免疫反應是遏制和消除感染的自然防禦機制。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 57103萬美元
2028 年市場規模 87484萬美元
2023-2028 年年複合成長率 7.22%
成長最快的細分市場 分子診斷
最大的市場 北美洲

敗血症診斷技術的進步

敗血症診斷技術的進步對於提高敗血症診斷的準確性、速度和效率至關重要。這些創新使醫療保健專業人員能夠更早地識別膿毒症並及時啟動治療，這對患者的治療結果至關重要。聚合酶鏈反應 (PCR) 技術可以快速檢測特定微生物 DNA 或 RNA，從而能夠高精度識別引起敗血症的病原體。下一代定序（NGS）技術有潛力同時識別多種病原體，並可用於檢測導致敗血症的已知和新型病原體。自動血液培養系統可自動執行檢測血液樣本中細菌或真菌生長的過程，比傳統的手動方法更快提供結果。帶有抗生素中和容器的血液培養瓶有助於克服血液中抗生素的抑製作用，促進敗血症患者微生物的恢復。免疫測定可以測量特定細胞因子的水平，例如降鈣素原 (PCT) 和 C 反應蛋白 (CRP)，它們被用作評估敗血症嚴重程度的生物標記。側流分析快速檢測可以在照護端檢測與敗血症相關的生物標記物，從而做出快速診斷和治療決策。分析宿主免疫反應的基因表現模式可以幫助識別敗血症並將其與其他發炎性疾病區分開來。 MicroRNA 光譜已顯示出作為膿毒症診斷標記物的前景。

帶有生物感測器的 POCT（即時檢測）設備可以檢測血液樣本中與敗血症相關的生物標記物，從而在床邊快速提供結果。微流控系統能夠有效處理小體積樣品，並且可以整合到攜帶式診斷設備中以進行敗血症檢測。人工智慧和機器學習演算法已應用於敗血症診斷。他們可以分析臨床資料、實驗室結果和生命徵象，以識別膿毒症的早期症狀，幫助早期介入。超音波、CT 掃描和 MRI 等先進的影像方式可以幫助識別感染跡象，例如膿瘍或器官損傷，從而有助於敗血症的診斷和監測。多重檢測可以同時測量與敗血症相關的多種生物標記物，提供更全面的診斷概況。先進的定序技術可以直接對臨床樣本中的細菌 DNA 進行定序，從而快速識別引起敗血症的特定病原體。在 COVID-19 大流行期間，遠距醫療平台和遠端監控技術變得更加重要，使醫療保健提供者能夠遠端監控患者並檢測敗血症的早期跡象。這一因素將有助於全球膿毒症診斷市場的發展。

敗血症病例上升

全球敗血症的發生率一直在上升。這可以歸因於人口老化、慢性病患者數量不斷增加以及抗生素抗藥性病原體的出現等因素。隨著越來越多的人面臨敗血症的風險，早期準確診斷的需求變得至關重要。大眾和醫療保健專業人員對敗血症的徵兆和症狀的認知不斷增強。認知的提高導致更多的人在懷疑敗血症時尋求醫療救助，從而導致更高的診斷需求。醫學科學技術的進步提高了對敗血症、其病理生理學以及早期診斷重要性的認知。醫療保健提供者更傾向於使用診斷工具來快速確認或排除敗血症。

監管機構和醫療機構越來越重視敗血症的早期發現和管理。這導致了指南的製定和採用，建議使用診斷測試來及時識別敗血症。由於能夠在患者床邊快速提供結果，對膿毒症即時檢測的需求不斷成長。這在急診和重症監護機構中尤其有價值，因為及時診斷至關重要。敗血症治療的進展，例如新的抗生素和療法，強調了準確診斷以針對引起感染的特定病原體制定治療方案的重要性。醫療基礎設施和實驗室設施的改進使得敗血症診斷測試​​的進行變得更加容易，即使在資源有限的環境中也是如此。醫療保健界一直致力於採取感染控制和預防措施，以減少敗血症的發生率，但早期發現仍然至關重要。有效的預防和早期診斷相輔相成，可以減少敗血症病例。像 COVID-19 大流行這樣的事件凸顯了診斷在管理包括敗血症在內的傳染病方面的關鍵作用。為了應對此類危機，人們對醫療保健基礎設施和診斷進行了投資。這項因素將加速全球膿毒症診斷市場的需求。

院內感染的發生率不斷增加

院內感染是患者在醫療機構（包括醫院和療養院）逗留期間所獲得的感染。如果不及時發現和治療，這些感染通常會發展為敗血症。由於免疫系統減弱、外科手術、侵入性醫療設備（例如導管）和住院時間延長等因素，醫療機構中的患者發生感染的風險較高。如果這些感染沒有及時識別和治療，它們可能會發展為敗血症。早期發現 HAI 及其潛在進展為敗血症對於患者安全至關重要。敗血症診斷在識別有敗血症風險的患者方面發揮著至關重要的作用，以便及時介入和治療。醫療機構實施嚴格的感染控制措施，以減少醫院感染的發生率。這些措施的一部分包括監測和早期發現感染。膿毒症診斷有助於此監測過程，有助於預防膿毒症的發展。在某些情況下，醫療機構可能會爆發特定感染，例如抗甲氧西林金黃色葡萄球菌 (MRSA) 或艱難梭菌 (C. diff) 感染。快速且準確地診斷這些疫情對於遏止傳播和預防敗血症病例至關重要。

醫療機構須遵守強制監測和報告 HAI 的監管要求和指南。遵守這些法規通常涉及使用敗血症診斷來追蹤感染率和結果。醫院和醫療保健提供者優先考慮患者安全並努力改善臨床結果。及時診斷和管理 HAI 引起的膿毒症病例是這些努力的關鍵組成部分。 HAI 引起的敗血症會因住院時間延長、重症監護治療和額外的醫療干涉而顯著增加醫療費用。及時診斷和介入有助於減輕醫療保健系統的經濟負擔。病患權益團體和組織提高了人們對 HAI 風險和感染控制重要性的認知。這導致人們更加關注並強調醫療機構中有效膿毒症診斷的必要性。這項因素將加速全球膿毒症診斷市場的需求。

主要市場挑戰

通用競爭

當通用替代品可用於診斷測試時，它們的價格通常比品牌產品更低。這可能會導致市場價格下跌，對生產品牌膿毒症診斷測試​​的公司的收入和利潤率帶來壓力。學名藥製造商可以透過提供具有成本效益的品牌膿毒症診斷測試​​替代品來佔領重要的市場佔有率。這種競爭可能會影響現有診斷公司的市場佔有率，並可能限制其成長前景。診斷公司通常會在研發上投入大量資源，以創造創新的敗血症診斷技術。一旦專利和獨佔權到期，學名藥製造商就可以合法生產和銷售類似的診斷測試，從而降低原始創新者的競爭優勢。為了與學名藥競爭，品牌敗血症診斷公司可能需要調整其定價策略，這可能會影響其獲利能力。降低價格以保持競爭力可能是必要的，但這可能會影響整體市場動態。學名藥競爭的存在可能會阻止公司投資於新的和改進的膿毒症診斷技術的研發。這可能會減慢該領域的創新並限制先進診斷工具的引入。雖然通用診斷測試旨在提供具有成本效益的替代方案，但人們可能會擔心這些產品的品質、可靠性和準確性。監管機構在確保通用測試符合必要的品質和安全標準方面發揮著至關重要的作用。

不利影響

膿毒症診斷中使用的一些診斷程序（例如血液培養採集）可能是侵入性的，並且存在不適、感染或其他併發症的風險。雖然這些程序對於準確診斷是必要的，但醫療保健提供者應採取適當的預防措施以盡量減少風險。頻繁抽血進行診斷測試可能會導致潛在的不適和併發症，特別是對於重症患者。應有效管理與血液採集相關的風險，例如血腫形成或穿刺部位感染。診斷測試，尤其是在重症監護或緊急情況下，可能會給患者帶來焦慮和壓力。對於醫療保健提供者來說，有效溝通並為接受敗血症診斷的患者提供情感支持至關重要。在某些情況下，可能存在過度使用敗血症診斷測試​​的風險，這可能會給患者帶來不必要的不​​良和費用。有效的臨床指南和決策支援工具對於確保適當的測試利用至關重要。診斷後，膿毒症患者需要持續監測和管理。雖然這本身並不是不良反應，但它是膿毒症護理中預防併發症和最佳化患者預後的關鍵方面。

主要市場趨勢

生物標記發現

與傳統的臨床徵兆和症狀相比，生物標記提供了一種更精確、更具體的方法來識別敗血症。這可以實現更早、更準確的診斷，從而及時進行干涉。敗血症可能會出現與其他疾病重疊的症狀。膿毒症特有的生物標記有助於將其與非膿毒症區分開來，從而降低誤診的風險。某些生物標記可以顯示敗血症的嚴重程度，幫助醫療保健提供者評估器官功能障礙的程度並相應地調整治療方案。生物標記可用於監測膿毒症的進展，從而根據需要調整治療計劃。生物標記的發現有助於膿毒症護理中個人化醫療的趨勢。根據患者的特定生物標記特徵量身訂做治療可以帶來更有效和更有針對性的干涉措施。膿毒症新型生物標記的鑑定一直是研究和開發工作的重點。這導致新的診斷測試和產品被引入市場。同時測量多種生物標記的多重測定已受到歡迎。這些面板可以提供更全面的診斷資料並提高敗血症診斷的準確性。研究表明，使用 microRNA 光譜作為敗血症的診斷標記物具有前景。 MicroRNA 生物標記可以提供有關宿主對感染反應的有價值的資訊。

細分市場洞察

技術洞察

2022 年，全球敗血症診斷市場將由微生物學技術領域主導，預計未來幾年將繼續擴大。這可能與以下事實有關：在微生物學技術中使用培養基測試可以精確檢測和識別細菌以進行敗血症診斷。重要參與者的新策略措施也推動了該領域的擴張。例如，2019年4月，BD推出了全新的BD BACTEC血小板品質控制介質，該介質有助於檢測和減少接受血小板輸注的患者中的敗血症。

產品洞察

2022 年，全球敗血症診斷市場將由血液培養基產品領域主導，預計未來幾年將持續擴大。在預測期內，該細分市場預計將保持領先地位。這是因為臨床醫師將血液培養視為最實用、最經濟的檢測方法。全球市場依類型分為三個產品類別：儀器、血液培養基、檢測試劑盒和試劑。在泰國一項針對敗血症患者的研究中，發現基於 PCR 的技術 Septifast 檢測作為診斷工具比血液培養表現更好。

診斷方法見解

2022 年，全球膿毒症診斷市場將由傳統診斷領域主導，預計未來幾年將繼續擴大。診斷敗血症的傳統方法取決於醫療保健專業人員的知識來評估患者的臨床表現並解讀實驗室和影像結果。必須快速識別和治療膿毒症，以改善患者的治療效果。

病原體洞察

2022年，全球敗血症診斷市場最大佔有率由細菌性敗血症領域主導，預計未來幾年將持續擴大。由於外科手術的增加、醫院傳播感染的增加以及細菌性敗血症病例的增加。根據SAGE Journals 2019 年1 月發布的報告，細菌性敗血症是最常見的形式，62.2% 的患者患有革蘭氏陰性菌，46.8% 的患者患有革蘭氏陽性菌。市場分為細菌性敗血症、真菌性敗血症和真菌性敗血症。膿毒症和其他基於病原體的膿毒症。在預測期內，預計革蘭氏陰性菌細分市場將引領細菌性敗血症細分市場。

區域洞察

到 2022 年，北美地區將主導全球敗血症診斷市場。在整個預測期內，預計該地區將保持領先地位。這一發展可能與該地區由於擁有強大的醫療基礎設施而增加使用先進的診斷工具有關。此外，重要競爭對手的大量存在和有利的報銷制度也推動了該領域的市場擴張。此外，預計傳染病和敗血症盛行率的上升將增加對尖端診斷方法的需求。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球膿毒症診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按技術（分子診斷、微生物學、免疫測定和其他技術）
    • 按產品（儀器、測定和試劑以及其他產品）
    • 依診斷方法（常規診斷和自動診斷）
    • 依病原體（細菌敗血症、真菌敗血症和其他病原體）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美敗血症診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按產品分類
    • 按診斷方法
    • 依病原體
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲敗血症診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按產品分類
    • 按診斷方法
    • 依病原體
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區敗血症診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按產品分類
    • 按診斷方法
    • 依病原體
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲敗血症診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按產品分類
    • 按診斷方法
    • 依病原體
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲敗血症診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按產品分類
    • 按診斷方法
    • 依病原體
    • 按國家/地區
  • MEA：國家分析
    • 南非敗血症診斷
    • 沙烏地阿拉伯敗血症診斷
    • 阿拉伯聯合大公國膿毒症診斷

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購

第 13 章：全球膿毒症診斷市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代治療類型的威脅

第15章：競爭格局

  • 商業概覽
  • 服務內容
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Abbott Laboratories Inc.
    • DiaSorin SpA
    • Becton, Dickinson and Company
    • BioMerieux Inc.
    • F. Hoffmann-La Roche AG
    • Danaher Corporation
    • Thermo Fisher Scientific Inc
    • Siemens Healthineers AG
    • Seegene, Inc.
    • Roche Diagnostics Corporation

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 16288

Global Sepsis Diagnostics Market has valued at USD 685.30 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.22% through 2028. Sepsis is a life-threatening medical condition that occurs when the body's response to infection becomes dysregulated, leading to widespread inflammation and potentially causing multiple organ dysfunction or failure. It is a severe and rapidly progressing condition that requires immediate medical attention and treatment. Sepsis typically begins with an infection, which can be caused by bacteria, viruses, fungi, or parasites. The infection can originate from various sources, such as a wound, urinary tract infection, respiratory infection, or an infected surgical site. When the body detects an infection, the immune system responds by releasing chemicals to fight off the invading pathogens. This immune response is a natural defense mechanism to contain and eliminate the infection.

In sepsis, the immune response becomes dysregulated or overactive. Instead of effectively targeting the infection, the immune system goes into overdrive, releasing excessive amounts of inflammatory chemicals into the bloodstream. The increasing prevalence of sepsis cases worldwide has been a significant driver for the sepsis diagnostics market. Sepsis is a critical condition that requires early and accurate diagnosis for effective treatment. There has been a growing awareness among healthcare professionals and the general public about sepsis and its potential severity. This awareness has led to increased testing and diagnosis. Continuous advancements in diagnostic technologies, such as molecular diagnostics, immunoassays, and blood culture systems, have improved the accuracy and speed of sepsis diagnosis. These technological innovations have expanded the market by providing more reliable and efficient diagnostic tools. The aging global population is more susceptible to infections and sepsis. As the elderly population continues to grow, the demand for sepsis diagnostics is expected to rise.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 571.03 Million
Market Size 2028USD 874.84 Million
CAGR 2023-20287.22%
Fastest Growing SegmentMolecular Diagnostics
Largest MarketNorth America

Advancements in Sepsis Diagnostic Technologies

Advancements in sepsis diagnostic technologies have been crucial in improving the accuracy, speed, and efficiency of sepsis diagnosis. These innovations enable healthcare professionals to identify sepsis earlier and initiate timely treatment, which is critical for patient outcomes. Polymerase Chain Reaction (PCR) technology allows for the rapid detection of specific microbial DNA or RNA, enabling the identification of sepsis-causing pathogens with high accuracy. Next-Generation Sequencing (NGS) technology has the potential to identify a wide range of pathogens simultaneously and can be used to detect both known and novel pathogens responsible for sepsis. Automated Blood Culture Systems automate the process of detecting bacterial or fungal growth in blood samples, providing faster results than traditional manual methods. Blood Culture Bottles with Antibiotic Neutralization containers help overcome the inhibitory effects of antibiotics in the bloodstream, enhancing the recovery of microorganisms from septic patients. Immunoassays can measure the levels of specific cytokines, such as procalcitonin (PCT) and C-reactive protein (CRP), which are used as biomarkers to assess the severity of sepsis. Lateral Flow Assays rapid tests can detect sepsis-related biomarkers at the point of care, allowing for quick diagnosis and treatment decisions. Analyzing the gene expression patterns of the host's immune response can help identify sepsis and differentiate it from other inflammatory conditions. MicroRNA profiles have shown promise as diagnostic markers for sepsis.

POCT (Point-of-Care Testing) devices with biosensors can detect sepsis-related biomarkers in blood samples, providing rapid results at the bedside. Microfluidic systems enable the efficient processing of small sample volumes and can be integrated into portable diagnostic devices for sepsis detection. AI and machine learning algorithms have been applied to sepsis diagnostics. They can analyze clinical data, laboratory results, and vital signs to identify early signs of sepsis, aiding in early intervention. Advanced imaging modalities like ultrasound, CT scans, and MRI can help identify signs of infection, such as abscesses or organ damage, aiding in the diagnosis and monitoring of sepsis. Multiplex assays can simultaneously measure multiple biomarkers associated with sepsis, providing a more comprehensive diagnostic profile. Advanced sequencing technologies can directly sequence bacterial DNA in clinical samples, allowing for the rapid identification of specific pathogens causing sepsis. Telemedicine platforms and remote monitoring technologies have become more important during the COVID-19 pandemic, enabling healthcare providers to monitor patients remotely and detect early signs of sepsis. This factor will help in the development of Global Sepsis Diagnostics Market.

Rising cases of Sepsis

The global incidence of sepsis has been on the rise. This can be attributed to factors such as an aging population, a growing number of people with chronic illnesses, and the emergence of antibiotic-resistant pathogens. As more individuals are at risk of sepsis, the need for early and accurate diagnosis becomes crucial. There has been a growing awareness among the public and healthcare professionals about the signs and symptoms of sepsis. Increased awareness leads to more people seeking medical attention when they suspect sepsis, resulting in higher diagnostic demand. Advances in medical science and technology have improved the understanding of sepsis, its pathophysiology, and the importance of early diagnosis. Healthcare providers are more inclined to use diagnostic tools to confirm or rule out sepsis quickly.

Regulatory bodies and healthcare organizations have placed an increased emphasis on the early detection and management of sepsis. This has led to the development and adoption of guidelines that recommend the use of diagnostic tests to identify sepsis promptly. The demand for point-of-care testing for sepsis has grown due to its ability to provide rapid results at the patient's bedside. This is especially valuable in emergency departments and critical care settings, where timely diagnosis is critical. Advances in sepsis treatment, such as new antibiotics and therapies, have underscored the importance of accurate diagnosis to tailor treatment regimens to the specific pathogens causing the infection. Improvements in healthcare infrastructure and laboratory facilities have made it easier to perform sepsis diagnostic tests, even in resource-limited settings. The healthcare community has been working on infection control and prevention measures to reduce the incidence of sepsis, but early detection remains essential. Effective prevention and early diagnosis complement each other in reducing sepsis cases. Events like the COVID-19 pandemic have highlighted the critical role of diagnostics in managing infectious diseases, including sepsis. Investments in healthcare infrastructure and diagnostics have been made in response to such crises. This factor will pace up the demand of Global Sepsis Diagnostics Market.

Increasing Incidence of Hospital-Acquired Infections

Hospital-acquired infections are infections that patients acquire during their stay in a healthcare facility, including hospitals and nursing homes. These infections can often progress to sepsis if not promptly detected and treated. Patients in healthcare settings are at an elevated risk of developing infections due to factors such as weakened immune systems, surgical procedures, invasive medical devices (e.g., catheters), and prolonged hospital stays. If these infections are not promptly identified and treated, they can progress to sepsis. Early detection of HAIs and their potential progression to sepsis is critical for patient safety. Sepsis diagnostics play a crucial role in identifying patients at risk of developing sepsis, allowing for timely intervention and treatment. Healthcare facilities implement rigorous infection control measures to reduce the incidence of HAIs. Part of these measures includes monitoring and early detection of infections. Sepsis diagnostics aid in this monitoring process, helping to prevent the development of sepsis. In some cases, healthcare facilities may experience outbreaks of specific infections, such as methicillin-resistant Staphylococcus aureus (MRSA) or Clostridium difficile (C. diff) infections. Rapid and accurate diagnosis of these outbreaks is essential to contain the spread and prevent sepsis cases.

Healthcare facilities are subject to regulatory requirements and guidelines that mandate the monitoring and reporting of HAIs. Compliance with these regulations often involves using sepsis diagnostics to track infection rates and outcomes. Hospitals and healthcare providers prioritize patient safety and strive to improve clinical outcomes. Timely diagnosis and management of sepsis cases resulting from HAIs are key components of these efforts. Sepsis resulting from HAIs can significantly increase healthcare costs due to prolonged hospital stays, intensive care treatment, and additional medical interventions. Timely diagnosis and intervention can help reduce the economic burden on healthcare systems. Patient advocacy groups and organizations have raised awareness about the risks of HAIs and the importance of infection control. This has led to increased scrutiny and emphasis on the need for effective sepsis diagnostics in healthcare settings. This factor will accelerate the demand of Global Sepsis Diagnostics Market.

Key Market Challenges

Generic Competition

When generic alternatives become available for diagnostic tests, they often come at a lower price than branded products. This can lead to price erosion in the market, putting pressure on the revenues and profit margins of companies manufacturing branded sepsis diagnostic tests. Generic manufacturers can capture a significant share of the market by offering cost-effective alternatives to branded sepsis diagnostic tests. This competition can affect the market share of existing diagnostic companies and potentially limit their growth prospects. Diagnostic companies typically invest substantial resources in research and development to create innovative sepsis diagnostic technologies. Once patents and exclusivity rights expire, generic manufacturers can legally produce and market similar diagnostic tests, reducing the competitive advantage of the original innovator. To compete with generics, branded sepsis diagnostic companies may need to adjust their pricing strategies, which can impact their profitability. Lowering prices to remain competitive may be necessary, but it can affect the overall market dynamics. The presence of generic competition can deter companies from investing in research and development for new and improved sepsis diagnostic technologies. This can slow down innovation in the field and limit the introduction of advanced diagnostic tools. While generic diagnostic tests aim to provide cost-effective alternatives, there may be concerns about the quality, reliability, and accuracy of these products. Regulatory bodies play a crucial role in ensuring that generic tests meet the necessary quality and safety standards.

Adverse Effects

Some diagnostic procedures used in sepsis diagnostics, such as blood culture collection, may be invasive and carry a risk of discomfort, infection, or other complications. While these procedures are necessary for accurate diagnosis, healthcare providers should take appropriate precautions to minimize risks. Frequent blood drawers for diagnostic tests can lead to potential discomfort and complications, especially in critically ill patients. The risks associated with blood collection, such as hematoma formation or infection at the puncture site, should be managed effectively. Diagnostic testing, especially in an intensive care or emergency setting, can cause anxiety and stress for patients. It is essential for healthcare providers to communicate effectively and provide emotional support to patients undergoing sepsis diagnostics. In some cases, there may be a risk of overusing diagnostic tests for sepsis, which can lead to unnecessary discomfort and costs for patients. Effective clinical guidelines and decision support tools are essential to ensure appropriate test utilization. Following diagnosis, patients with sepsis require continuous monitoring and management. While this is not an adverse effect per se, it is a critical aspect of sepsis care to prevent complications and optimize patient outcomes.

Key Market Trends

Biomarker Discovery

Biomarkers provide a more precise and specific way to identify sepsis compared to traditional clinical signs and symptoms. This can lead to earlier and more accurate diagnosis, allowing for timely intervention. Sepsis can present with symptoms that overlap with other medical conditions. Biomarkers that are specific to sepsis help differentiate it from non-septic conditions, reducing the risk of misdiagnosis. Certain biomarkers can indicate the severity of sepsis, helping healthcare providers assess the level of organ dysfunction and tailor treatment accordingly. Biomarkers can be used to monitor the progression of sepsis, allowing for adjustments in treatment plans as needed. Biomarker discovery contributes to the trend of personalized medicine in sepsis care. Tailoring treatment based on a patient's specific biomarker profile can lead to more effective and targeted interventions. The identification of novel biomarkers for sepsis has been a focus of research and development efforts. This has led to the introduction of new diagnostic tests and products onto the market. Multiplex assays that measure multiple biomarkers simultaneously have gained popularity. These panels can provide a more comprehensive diagnostic profile and improve the accuracy of sepsis diagnosis. Research has shown promise in using microRNA profiles as diagnostic markers for sepsis. MicroRNA biomarkers can provide valuable information about the host response to infection.

Segmental Insights

Technology Insights

In 2022, the Global Sepsis Diagnostics Market dominated by microbiology technology segment and is predicted to continue expanding over the coming years. This might be linked to the fact that the use of culture medium tests in microbiology technology enables precise detection and identification of bacteria for sepsis diagnosis. New strategic initiatives by important players are also fuelling the segment's expansion. For instance, in April 2019, BD introduced its brand-new BD BACTEC platelet quality control media, which aids in the detection and reduction of sepsis among patients getting platelet transfusions.

Product Insights

In 2022, the Global Sepsis Diagnostics Market dominated by blood culture media product segment and is predicted to continue expanding over the coming years. Over the forecast period, the segment is anticipated to keep up its lead. This is because clinicians view blood cultures as the most practical and economical testing method. The global market has been divided into three product categories based on type: instruments, blood culture media, and test kits & reagents. In a study on sepsis patients in Thailand, it was found that the Septifast assay, a PCR-based technique, performed better as a diagnostic tool than Blood Culture.

Diagnostic Method Insights

In 2022, the Global Sepsis Diagnostics Market dominated by conventional diagnostics segment and is predicted to continue expanding over the coming years. The traditional approach to diagnosing sepsis depends on the knowledge of healthcare professionals to assess the patient's clinical presentation and decipher lab and imaging results. Sepsis must be quickly identified and treated to enhance patient outcomes.

Pathogen Insights

In 2022, the Global Sepsis Diagnostics Market largest share was dominated by bacterial sepsis segment in the forecast period and is predicted to continue expanding over the coming years. Due to the increase in surgical operations, the growth in hospital-transmitted infections, and the rise in cases of bacterial sepsis. Bacterial sepsis is the most frequent form, with 62.2% of patients having gram-negative bacteria and 46.8% having gram-positive bacteria, according to a report released by SAGE Journals in January 2019. The market is divided into categories for bacterial sepsis, fungal sepsis, and other pathogen-based sepsis. Over the course of the projection period, it is predicted that the gram-negative bacteria sub-segment will lead the market in the bacterial sepsis segment.

Regional Insights

The North America region dominates the Global Sepsis Diagnostics Market in 2022. Throughout the predicted period, it is anticipated that the region would keep up its lead. This development can be linked to the region's increased use of advanced diagnostic tools due to the presence of a strong healthcare infrastructure. Additionally, the market expansion in this area is being fueled by the substantial presence of important competitors and a favorable reimbursement system. Additionally, it is anticipated that the rising prevalence of infectious illnesses and sepsis will increase the need for cutting-edge diagnostic methods.

Key Market Players

  • Abbott Laboratories Inc.
  • DiaSorin SpA
  • Becton, Dickinson, and Company
  • BioMerieux Inc.
  • F. Hoffmann-La Roche AG
  • Danaher Corporation
  • Thermo Fisher Scientific Inc
  • Siemens Healthineers AG
  • Seegene, Inc.
  • Roche Diagnostics Corporation

Report Scope:

In this report, the Global Sepsis Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Sepsis Diagnostics Market, By Technology:

  • Molecular Diagnostics
  • Microbiology
  • Immunoassay
  • Other Technologies

Sepsis Diagnostics Market, By Product:

  • Instruments
  • Assays and Reagents
  • Other Products

Sepsis Diagnostics Market, By Diagnostic Method:

  • Conventional Diagnostics
  • Automated Diagnostics

Sepsis Diagnostics Market, By Pathogen:

  • Bacterial Sepsis
  • Fungal Sepsis
  • Other Pathogens

Global Sepsis Diagnostics Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Sepsis Diagnostics Market.

Available Customizations:

  • Global Sepsis Diagnostics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Sepsis Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Molecular Diagnostics, Microbiology, Immunoassay, and Other Technologies)
    • 5.2.2. By Product (Instruments, Assays and Reagents, and Other Products)
    • 5.2.3. By Diagnostic Method (Conventional Diagnostics and Automated Diagnostics)
    • 5.2.4. By Pathogen (Bacterial Sepsis, Fungal Sepsis, and Other Pathogens)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Sepsis Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Product
    • 6.2.3. By Diagnostic Method
    • 6.2.4. By Pathogen
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Sepsis Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Diagnostic Method
        • 6.3.1.2.4. By Pathogen
    • 6.3.2. Canada Sepsis Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Diagnostic Method
        • 6.3.2.2.4. By Pathogen
    • 6.3.3. Mexico Sepsis Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Diagnostic Method
        • 6.3.3.2.4. By Pathogen

7. Europe Sepsis Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Product
    • 7.2.3. By Diagnostic Method
    • 7.2.4. By Pathogen
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Sepsis Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Diagnostic Method
        • 7.3.1.2.4. By Pathogen
    • 7.3.2. United Kingdom Sepsis Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Diagnostic Method
        • 7.3.2.2.4. By Pathogen
    • 7.3.3. Italy Sepsis Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Diagnostic Method
        • 7.3.3.2.4. By Pathogen
    • 7.3.4. France Sepsis Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Diagnostic Method
        • 7.3.4.2.4. By Pathogen
    • 7.3.5. Spain Sepsis Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Diagnostic Method
        • 7.3.5.2.4. By Pathogen

8. Asia-Pacific Sepsis Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Product
    • 8.2.3. By Diagnostic Method
    • 8.2.4. By Pathogen
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Sepsis Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Diagnostic Method
        • 8.3.1.2.4. By Pathogen
    • 8.3.2. India Sepsis Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Diagnostic Method
        • 8.3.2.2.4. By Pathogen
    • 8.3.3. Japan Sepsis Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Diagnostic Method
        • 8.3.3.2.4. By Pathogen
    • 8.3.4. South Korea Sepsis Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Diagnostic Method
        • 8.3.4.2.4. By Pathogen
    • 8.3.5. Australia Sepsis Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Diagnostic Method
        • 8.3.5.2.4. By Pathogen

9. South America Sepsis Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Product
    • 9.2.3. By Diagnostic Method
    • 9.2.4. By Pathogen
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Sepsis Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Diagnostic Method
        • 9.3.1.2.4. By Pathogen
    • 9.3.2. Argentina Sepsis Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Diagnostic Method
        • 9.3.2.2.4. By Pathogen
    • 9.3.3. Colombia Sepsis Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Diagnostic Method
        • 9.3.3.2.4. By Pathogen

10. Middle East and Africa Sepsis Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Product
    • 10.2.3. By Diagnostic Method
    • 10.2.4. By Pathogen
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Sepsis Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Diagnostic Method
        • 10.3.1.2.4. By Pathogen
    • 10.3.2. Saudi Arabia Sepsis Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Diagnostic Method
        • 10.3.2.2.4. By Pathogen
    • 10.3.3. UAE Sepsis Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Diagnostic Method
        • 10.3.3.2.4. By Pathogen

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions

13. Global Sepsis Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Abbott Laboratories Inc.
    • 15.5.2. DiaSorin SpA
    • 15.5.3. Becton, Dickinson and Company
    • 15.5.4. BioMerieux Inc.
    • 15.5.5. F. Hoffmann-La Roche AG
    • 15.5.6. Danaher Corporation
    • 15.5.7. Thermo Fisher Scientific Inc
    • 15.5.8. Siemens Healthineers AG
    • 15.5.9. Seegene, Inc.
    • 15.5.10. Roche Diagnostics Corporation

16. Strategic Recommendations

17. About Us & Disclaimer